The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
Open accessAbstract
BACKGROUND: Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial. We further evaluated the efficacy of tofacitinib as induction and maintenance therapy. METHODS: We conducted three phase 3, randomized, double-blind, placebo-controlled trials of tofacitinib therapy in adults with ulcerative colitis. In the OCTAVE Induction 1 and 2 trials, 598 and 541 patients, respectively, who had moderately to severely active ulcerative colitis despite previous conventional therapy or therapy with a tumor necrosis factor antagonist were randomly assigned to receive induction therapy with tofacitinib (10 mg twice daily) or placebo for 8 weeks. The primary end point was remission at 8 weeks. In the OCTAVE Sustain trial, 593 patients who had a clinical response to induction therapy were randomly assigned to receive maintenance therapy with tofacitinib (either 5 mg or 10 mg twice daily) or placebo for 52 weeks. The primary end point was remission at 52 weeks. RESULTS: In the OCTAVE Induction 1 trial, remission at 8 weeks occurred in 18.5% of the patients in the tofacitinib group versus 8.2% in the placebo group (P=0.007); in the OCTAVE Induction 2 trial, remission occurred in 16.6% versus 3.6% (P<0.001). In the OCTAVE Sustain trial, remission at 52 weeks occurred in 34.3% of the patients in the 5-mg tofacitinib group and 40.6% in the 10-mg tofacitinib group versus 11.1% in the placebo group (P<0.001 for both comparisons with placebo). In the OCTAVE Induction 1 and 2 trials, the rates of overall infection and serious infection were higher with tofacitinib than with placebo. In the OCTAVE Sustain trial, the rate of serious infection was similar across the three treatment groups, and the rates of overall infection and herpes zoster infection were higher with tofacitinib than with placebo. Across all three trials, adjudicated nonmelanoma skin cancer occurred in five patients who received tofacitinib and in one who received placebo, and adjudicated cardiovascular events occurred in five who received tofacitinib and in none who received placebo; as compared with placebo, tofacitinib was associated with increased lipid levels. CONCLUSIONS: In patients with moderately to severely active ulcerative colitis, tofacitinib was more effective as induction and maintenance therapy than placebo. (Funded by Pfizer; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain ClinicalTrials.gov numbers, NCT01465763 , NCT01458951 , and NCT01458574 , respectively.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis
Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198712243172603 · Cited by 3,026
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Feagan, B. G., Rutgeerts, P., Sands, B. E., Hanauer, S., Colombel, J.-F., Sandborn, W. J., Van Assche, G., Axler, J., Kim, H.-J., Danese, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215734 · Cited by 2,888
Self-citationOrdás, I., Eckmann, L., Talamini, M., Baumgart, D. C., & Sandborn, W. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60150-0 · Cited by 2,078
Self-citationKornbluth, A., & Sachar, D. B. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.727 · Cited by 2,023
Dignass, A., Lindsay, J. O., Sturm, A., Windsor, A., Colombel, J.-F., Allez, M., D'Haens, G., D'Hoore, A., Mantzaris, G., Novacek, G., et al. (2012) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.002 · Cited by 1,548
Self-citationD’Haens, G., Sandborn, W. J., Feagan, B. G., Geboes, K., Hanauer, S. B., Irvine, E. J., Lémann, M., Marteau, P., Rutgeerts, P., Schölmerich, J., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.12.038 · Cited by 1,207
Self-citationTofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
Sandborn, W. J., Ghosh, S., Panes, J., Vranic, I., Su, C., Rousell, S., & Niezychowski, W. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112168 · Cited by 800
Self-citationClark, J. D., Flanagan, M. E., & Telliez, J.-B. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401490p · Cited by 601
Ordás, I., Mould, D. R., Feagan, B. G., & Sandborn, W. J. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.328 · Cited by 498
Self-citationBachelez, H., van de Kerkhof, P. C. M., Strohal, R., Kubanov, A., Valenzuela, F., Lee, J.-H., Yakusevich, V., Chimenti, S., Papacharalambous, J., Proulx, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62113-9 · Cited by 410
Cited by
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
Kobayashi, T., Siegmund, B., Le Berre, C., Wei, S. C., Ferrante, M., Shen, B., Bernstein, C. N., Danese, S., Peyrin-Biroulet, L., & Hibi, T. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0205-x · Cited by 1,649
Self-citationLe Berre, C., Honap, S., & Peyrin-Biroulet, L. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00966-2 · Cited by 1,643
ACG Clinical Guideline: Ulcerative Colitis in Adults
Rubin, D. T., Ananthakrishnan, A. N., Siegel, C. A., Sauer, B. G., & Long, M. D. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000152 · Cited by 1,577
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266
Mechanisms of Disease: Inflammatory Bowel Diseases
Ramos, G. P., & Papadakis, K. A. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.09.013 · Cited by 1,021
Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD
Na, Y. R., Stakenborg, M., Seok, S. H., & Matteoli, G. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0172-4 · Cited by 900
Ulcerative Colitis in Adults: A Review
Gros, B., & Kaplan, G. G. (2023) · JAMA · doi:10.1001/jama.2023.15389 · Cited by 738
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue, C., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 699
Evidence-based clinical practice guidelines for inflammatory bowel disease
Matsuoka, K., Kobayashi, T., Ueno, F., Matsui, T., Hirai, F., Inoue, N., Kato, J., Kobayashi, K., Kobayashi, K., Koganei, K., et al. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1439-1 · Cited by 698
Ward, M. M., Deodhar, A., Gensler, L. S., Dubreuil, M., Yu, D., Khan, M. A., Haroon, N., Borenstein, D., Wang, R., Biehl, A., et al. (2019) · Arthritis Care & Research · doi:10.1002/acr.24025 · Cited by 693
Self-citationTreatment of Inflammatory Bowel Disease: A Comprehensive Review
Cai, Z., Wang, S., & Li, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.765474 · Cited by 675
Danese, S., Vermeire, S., Zhou, W., Pangan, A. L., Siffledeen, J., Greenbloom, S., Hébuterne, X., D'Haens, G., Nakase, H., Panés, J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00581-5 · Cited by 643
Self-citationA comprehensive review and update on ulcerative colitis,
Gajendran, M., Loganathan, P., Jimenez, G., Catinella, A. P., Ng, N., Umapathy, C., Ziade, N., & Hashash, J. G. (2019) · Disease-a-Month · doi:10.1016/j.disamonth.2019.02.004 · Cited by 638
JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
Salas, A., Hernandez-Rocha, C., Duijvestein, M., Faubion, W., McGovern, D., Vermeire, S., Vetrano, S., & Vande Casteele, N. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0273-0 · Cited by 635
Self-citationWard, M. M., Deodhar, A., Gensler, L. S., Dubreuil, M., Yu, D., Khan, M. A., Haroon, N., Borenstein, D., Wang, R., Biehl, A., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.41042 · Cited by 623
Self-citationEvidence-based clinical practice guidelines for inflammatory bowel disease 2020
Nakase, H., Uchino, M., Shinzaki, S., Matsuura, M., Matsuoka, K., Kobayashi, T., Saruta, M., Hirai, F., Hata, K., Hiraoka, S., et al. (2021) · Journal of Gastroenterology · doi:10.1007/s00535-021-01784-1 · Cited by 505
Janus kinase-targeting therapies in rheumatology: A mechanisms-based approach
Tanaka, Y., Luo, Y., O’Shea, J. J., & Nakayamada, S. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00726-8 · Cited by 501
Feagan, B. G., Danese, S., Loftus, E. V., Vermeire, S., Schreiber, S., Ritter, T., Fogel, R., Mehta, R., Nijhawan, S., Kempiński, R., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00666-8 · Cited by 462
Self-citationThe influence of cytokines on the complex pathology of ulcerative colitis
Nakase, H., Sato, N., Mizuno, N., & Ikawa, Y. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.103017 · Cited by 443
The ‘cytokine storm’: molecular mechanisms and therapeutic prospects
Karki, R., & Kanneganti, T.-D. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.06.001 · Cited by 438
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia
Guimarães, P. O., Quirk, D., Furtado, R. H., Maia, L. N., Saraiva, J. F., Antunes, M. O., Kalil Filho, R., Junior, V. M., Soeiro, A. M., Tognon, A. P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101643 · Cited by 435
Feuerstein, J. D., Moss, A. C., & Farraye, F. A. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.018 · Cited by 398
Strategies for targeting cytokines in inflammatory bowel disease
Neurath, M. F. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-024-01008-6 · Cited by 398
Lasa, J. S., Olivera, P. A., Danese, S., & Peyrin-Biroulet, L. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00377-0 · Cited by 384
Self-citationMetabolic regulation of the immune system in health and diseases: mechanisms and interventions
Hu, T., Liu, C.-H., Lei, M., Zeng, Q., Li, L., Tang, H., & Zhang, N. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01954-6 · Cited by 383
Wrobleski, S. T., Moslin, R., Lin, S., Zhang, Y., Spergel, S., Kempson, J., Tokarski, J. S., Strnad, J., Zupa-Fernandez, A., Cheng, L., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00444 · Cited by 382
Singh, S., Murad, M. H., Fumery, M., Dulai, P. S., & Sandborn, W. J. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.01.008 · Cited by 375
Self-citationNewer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease
Baumgart, D. C., & Le Berre, C. (2021) · New England Journal of Medicine · doi:10.1056/nejmra1907607 · Cited by 354
Moving towards personalized treatments of immune-related adverse events
Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0352-8 · Cited by 351
Segal, J. P., LeBlanc, J.-F., & Hart, A. L. (2021) · Clinical Medicine · doi:10.7861/clinmed.2021-0080 · Cited by 351
Olivera, P. A., Lasa, J. S., Bonovas, S., Danese, S., & Peyrin-Biroulet, L. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.001 · Cited by 330
Self-citationEfficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease
Sandborn, W. J., Feagan, B. G., Loftus, E. V., Peyrin-Biroulet, L., Van Assche, G., D’Haens, G., Schreiber, S., Colombel, J.-F., Lewis, J. D., Ghosh, S., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.047 · Cited by 322
Self-citationRobertson, C. C., Inshaw, J. R. J., Onengut-Gumuscu, S., Chen, W.-M., Santa Cruz, D. F., Yang, H., Cutler, A. J., Crouch, D. J. M., Farber, E., Bridges, S. L., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00880-5 · Cited by 302
IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment
Manore, S. G., Doheny, D. L., Wong, G. L., & Lo, H.-W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.866014 · Cited by 307
Current and future status of JAK inhibitors
McLornan, D. P., Pope, J. E., Gotlib, J., & Harrison, C. N. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00438-4 · Cited by 305
Nash, P., Kerschbaumer, A., Dörner, T., Dougados, M., Fleischmann, R. M., Geissler, K., McInnes, I., Pope, J. E., van der Heijde, D., Stoffer-Marx, M., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218398 · Cited by 299
JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
Fragoulis, G. E., McInnes, I. B., & Siebert, S. (2019) · Rheumatology · doi:10.1093/rheumatology/key276 · Cited by 296
Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis
Sandborn, W. J., Ghosh, S., Panes, J., Schreiber, S., D’Haens, G., Tanida, S., Siffledeen, J., Enejosa, J., Zhou, W., Othman, A. A., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.02.030 · Cited by 289
Self-citationSelective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases
Virtanen, A. T., Haikarainen, T., Raivola, J., & Silvennoinen, O. (2019) · BioDrugs · doi:10.1007/s40259-019-00333-w · Cited by 281
Gou, S., Huang, Y., Wan, Y., Ma, Y., Zhou, X., Tong, X., Huang, J., Kang, Y., Pan, G., Dai, F., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.05.012 · Cited by 277
Ulcerative Colitis—Diagnostic and Therapeutic Algorithms
Kucharzik, T., Koletzko, S., Kannengießer, K., & Dignaß, A. (2020) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2020.0564 · Cited by 268
Effector T Helper Cell Subsets in Inflammatory Bowel Diseases
Imam, T., Park, S., Kaplan, M. H., & Olson, M. R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01212 · Cited by 267
JAK inhibitors for the treatment of autoimmune and inflammatory diseases
Jamilloux, Y., El Jammal, T., Vuitton, L., Gerfaud-Valentin, M., Kerever, S., & Sève, P. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102390 · Cited by 264
Deodhar, A., Sliwinska-Stanczyk, P., Xu, H., Baraliakos, X., Gensler, L. S., Fleishaker, D., Wang, L., Wu, J., Menon, S., Wang, C., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-219601 · Cited by 259
Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression?
Villablanca, E. J., Selin, K., & Hedin, C. R. H. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00604-y · Cited by 256
New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology
Giraldez, M. D., Carneros, D., Garbers, C., Rose-John, S., & Bustos, M. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00473-x · Cited by 156
Pérez-Jeldres, T., Tyler, C. J., Boyer, J. D., Karuppuchamy, T., Yarur, A., Giles, D. A., Yeasmin, S., Lundborg, L., Sandborn, W. J., Patel, D. R., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00212 · Cited by 126
Self-citationSafety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases
Núñez, P., Quera, R., & Yarur, A. J. (2023) · Drugs · doi:10.1007/s40265-023-01840-5 · Cited by 111
Nowak, J. K., Adams, A. T., Kalla, R., Lindstrøm, J. C., Vatn, S., Bergemalm, D., Keita, Å. V., Gomollón, F., Jahnsen, J., Vatn, M. H., et al. (2022) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjac033 · Cited by 51
The Role of Filgotinib in Ulcerative Colitis and Crohn’s Disease
Fanizza, J., D’Amico, F., Lauri, G., Martinez-Dominguez, S. J., Allocca, M., Furfaro, F., Zilli, A., Fiorino, G., Parigi, T. L., Radice, S., et al. (2024) · Immunotherapy · doi:10.2217/imt-2023-0116 · Cited by 16
Self-citation
Metadata
- Authors
- Sandborn, W. J., Su, C., Sands, B. E., D’Haens, G. R., Vermeire, S., Schreiber, S., Danese, S., Feagan, B. G., Reinisch, W., Niezychowski, W., Friedman, G., Lawendy, N., Yu, D., Woodworth, D., Mukherjee, A., Zhang, H., Healey, P., & Panés, J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-05-04
- Volume
- 376
- Issue
- 18
- Pages
- 1723-1736
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2611548364
- Cited by
- 1,770
- References
- 22
- FWCI
- 91.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.